Results 51 to 60 of about 456,969 (387)

Many faces of DAMPs in cancer therapy [PDF]

, 2013
A new concept of immunogenic cell death (ICD) has recently been proposed. The immunogenic characteristics of this cell death mode are mediated mainly by molecules called ‘damage-associated molecular patterns’ (DAMPs), most of which are recognized by ...
Aaes, Tania Love, Bachert, Claus, Krysko, Dmitri, Krysko, Olga, Vandenabeele, Peter   +4 more
core   +1 more source

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

Nature Communications, 2017
Radiotherapy is under investigation for its ability to enhance responses to immunotherapy. However, the mechanisms by which radiation induces anti-tumour T cells remain unclear.
C. Vanpouille-Box, A. Alard, M. Aryankalayil, Yasmeen Sarfraz, J. Diamond, R. Schneider, G. Inghirami, C. Coleman, S. Formenti, S. Demaria   +9 more
semanticscholar   +1 more source

Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

Frontiers in Immunology, 2021
There is a significant research gap in meta-analysis on the efficacy and safety of coronavirus disease 2019 (COVID-19) vaccines. This study analyzed the efficacy of COVID-19 vaccines. Published phase I, phase II, and phase III trials analyzing safety and
N. Sharif, Khalid J. Alzahrani, Shamsun Nahar Ahmed, S. Dey   +3 more
semanticscholar   +1 more source

Immunogenicity of botulinum toxins [PDF]

Journal of Neural Transmission, 2012
Botulinum neurotoxins are formulated biologic pharmaceuticals used therapeutically to treat a wide variety of chronic conditions, with varying governmental approvals by country. Some of these disorders include cervical dystonia, post-stroke spasticity, blepharospasm, migraine, and hyperhidrosis.
Naumann, Markus, Boo, Lee Ming, Ackerman, Alan H., Gallagher, Conor J.   +3 more
openaire   +3 more sources

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

Journal of Immunology Research, 2016
Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity.
Anshu Kuriakose, Narendra Chirmule, Pradip Nair   +2 more
doaj   +1 more source

An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8+ T cells and antibody when expressed from modified vaccinia Ankara [PDF]

, 2014
Dengue is a global public health concern and this is aggravated by a lack of vaccines or antiviral therapies. Despite the well-known role of CD8(+) T cells in the immunopathogenesis of Dengue virus (DENV), only recent studies have highlighted the ...
Coelho, Fabiana M., da Fonseca, Flávio G., Flesch, Inge E. A., Pinho, Tânia M. G., Quinan, Bárbara R., Tscharke, David C.   +5 more
core   +1 more source

Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults [PDF]

, 2016
Background: Non-typeable Haemophilus influenzae (NTHi) is a major cause of various respiratory diseases. The development of an effective vaccine against NTHi mandates new approaches beyond conjugated vaccines as this opportunistic bacterium is non ...
Aris, Emmanuel, Caubet, Magalie, Devaster, Jeanne-Marie, Haazen, Wouter, Leroux-Roels, Geert, Peeters, Mathieu, Shakib, Sepehr, Van Damme, Pierre   +7 more
core   +2 more sources

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications, 2020
The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease.
Trevor R. F. Smith, Ami Patel, S. Ramos, Dustin Elwood, Xizhou Zhu, Jian Yan, E. Gary, Susanne N. Walker, K. Schultheis, M. Purwar, Ziyang Xu, Jewell N. Walters, Pratik S. Bhojnagarwala, Maria Yang, Neethu Chokkalingam, P. Pezzoli, Elizabeth M. Parzych, E. Reuschel, Arthur Doan, Nicholas J. Tursi, Miguel A. Vasquez, Jihae Choi, Edgar Tello-Ruiz, I. Maričić, Mamadou A. Bah, Yuanhan Wu, D. Amante, Daniel H. Park, Yaya D. Dia, A. Ali, F. Zaidi, Alison Generotti, Kevin Y. Kim, T. Herring, Sophia M. Reeder, V. Andrade, K. Buttigieg, Gan Zhao, Jiun‐Ming Wu, Dan Li, L. Bao, Jiangning Liu, Wei Deng, C. Qin, Ami Shah Brown, M. Khoshnejad, Nianshuang Wang, Jacqueline D. Chu, D. Wrapp, Jason S. McLellan   +49 more
semanticscholar   +1 more source

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +3 more sources

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

Molecular Therapy: Methods & Clinical Development, 2022
Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events observed in clinical development have been implicated with host immune responses against ...
Tong-yuan Yang, Manuela Braun, Wibke Lembke, Fraser McBlane, John Kamerud, Stephen DeWall, Edit Tarcsa, Xiaodong Fang, Lena Hofer, Uma Kavita, Vijay V. Upreti, Swati Gupta, LiNa Loo, Alison J. Johnson, Rakesh Kantilal Chandode, Kay-Gunnar Stubenrauch, Maya Vinzing, Cindy Q. Xia, Vibha Jawa   +18 more
doaj